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ABSTRACT 
Liquisolid technique is the novel concept of drug delivery via the oral route. This technique is applied to poorly water soluble, water insoluble or liphophilic 
drugs. According to the new formulation method of liquisolid compacts, liquid medications such as solutions or suspensions of water insoluble drugs in 
suitable non-volatile vehicles can be converted into acceptably flowing and compressible powders by blending with selected powder excipients.   The 
present  research  endeavor  is  directed  towards  the  development  of  liquisolid  compact  for  the  production  of  sustained  release  tablet  of  water-soluble 
Metoprolol succinate. Liquisolid compacts were prepared by using Tween 80 as the liquid vehicle or non-volatile solvent, Avicel PH 102 as absorbing 
carrier and Aerosil 200 as adsorbing coating material. The prepare dliquisolid systems were evaluated for their micromeretic properties and possible drug-
excipients interactions. P-XRD analysis confirmed that no change in crystallinity of Metoprolol succinate Liquisolid compacts. The DSC and IR spectra 
analysis study ruled out no any significant interaction between the drug and excipients used in preparation of Metoprolol succinate Liquisolid compacts. The 
tableting properties were falling within acceptable limits. The in vitro dissolution study confirmed reduction in drug release from Liquisolid compacts 
compared to conventional matrix tablet, in-vivo study was carried out to check the plasma drug concentration. Tween 80 has plasticizer effect by which it 
can reduce the glass transition temperature of polymer and impart flexibility in sustaining the release of drug from liquisolid matrices. The results showed 
that wet granulation had a remarkable impact on the release rate of Metoprolol succinate from liquisolid compacts, reducing the release rate of drug from 
liquisolid compacts. 
Key words: Metoprolol succinate, Liquisolid Tablets, Sustained Release, Avicel. 
 
INTRODUCTION 
Metoprolol succinate is a β1 (Cardio selective) blockers i.e. 
β- receptor antagonist acting as a competitive inhibitor of the 
action of catecholamine’s like noradrenalin at β-adrenergic 
receptor  sites.  It  is  widely  used  in  therapeutics  for  its 
antihypertensive  and  antiarrhythmic  properties.  It  is  also 
called as sympathetic and Anti adrenergic drugs. It is a water 
soluble drug having a half life about 3-4 hrs, which makes it 
a  suitable  candidate  to  be  delivered  at  a  controlled  rate. 
There  are  several  techniques  for  preparation  of  sustained 
release  formulations,  among  which  control  of  drug 
dissolution is one of the best and most successful methods 
due to its simplicity  and low cost (Jantzen  and Robinson, 
1996).  To  achieve  this  aim,  several  methods  have  been 
developed  such  as  preparation  of  salt  form  of  the  drug, 
coating  with  special  materials  and  incorporation  of  drugs 
into hydrophobic carriers. The term ‘liquisolid systems’ (LS) 
are  a  powdered  form  of  liquid  drug  formulated  by 
converting  liquid  Lipophilic  drug  or  drug  suspension  or 
solution  of  water-insoluble  solid  drug  in  suitable  non-
volatile  solvent  systems,  non  adherent,  free-flowing  and 
readily  compressible  powdered  mixtures  by  blending  with 
selected carrier and coating materials. 
The  present  work  was  focused  on  the  formulation  and 
evaluation  of  the  sustained  release  liquisolid  tablet  of 
metoprolol succinate. Sustain release tablet was formulated 
by using non volatile solvent such as tween 80 in which drug 
having  least  solubility,  matrix  formulation  done  by  using 
different  polymers  like  Hydroxypropyl  Methylcellulose 
(HPMC) and Avicel PH 102 as absorbing carrier and Aerosil 
200 as adsorbing coating material and evaluated for different 
in- vitro and in- vivo parameters along with development of 
RP-HPLC  method  for  estimation  of  Metoprolol  succinate 
from plasma. 
It is suggested here that the present research work has the 
potential  to  be  optimized  for  the  reduction  of  the  drug 
dissolution  rate  and  thereby  the  production  of  sustained 
release systems.  
 
MATERIALS AND METHODS 
Materials 
Metoprolol  succinate  was  provided  by  Cipla  Ltd. 
Patalganga, Raigad, Polyethylene glycol 400 (Research Lab, 
Mumbai), Propylene glycol, Acetonitrile (HPLC grade) and 
Methanol  (HPLC  grade)  provided  by  Finar  Chem.  Ltd. 
Ahmadabad, HPMC (Colorcon, Goa), Liquid paraffin (Loba 
Chem. Mumbai), Aerosil (Degussa India Pvt. Ltd.) Lactose 
(Research  Lab,  Mumbai),  Potassium  dehydrogenate  ortho 
phosphate (Loba Chem. Mumbai), Avicel PH 102 and 200 
(Maple Biotech Pvt. Ltd. Pune), Tween 80 (Research Lab, 
Mumbai). 
 
Preparation of metoprolol succinate conventional matrix 
tablets (MS-CMT)   
Metoprolol succinate CMT was prepared by mixing of drug 
with  Avicel-Silica  mixture  for  a  period  of  10  min  in  a 
mortar.  The  mixture was compressed on  a 13  mm  punch. 
Sufficient  compression  pressure  was  applied  in  order  to 
produce  tablets  with  the  hardness  around  4  kg/cm
2.  Each 
tablet contains 25 mg metoprolol succinate, 425 mg Avicel 
PH 102 as a carrier material, 21 mg of nm-sized silica as 
coating material and 10% HPMC as a binder.  
 
Preparation  of  metoprolol  succinate  Liquisolid  tablets/ 
compact (MS-LC) by wet granulation 
Nine batches of sustained release tablets, each containing 25 
mg Metoprolol succinate were prepared by wet granulation 
technique. The granules used for the preparation had good 
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were passed through sieve # 100. HPMC K15M 1% w/v was 
used as a binding agent. MS was dispersed in tween-80 to 
make  10-50%  w/w  solutions  (denoted  as  LS-1  to  LS-9). 
Then  a  binary  mixture  of  carrier  and  coating  material 
containing  Avicel  PH  102  as  the  carrier  material  and 
Aerosil-200 as the coating  material at a ratio of 20:1 was 
prepared.  The  binary  mixture  was  added  to  the  liquid 
medication  under  continuous  mixing  in  a  mortar.  After 
preparation of liquisolid systems, HPMC solution was added 
into the mixture to obtain wet mixture of powders. Then the 
mixture was granulated through sieve # 12 and kept at room 
temperature (25 ± 1 
0C) for 24 hrs. After this period, the 
dried mixture was sieved using sieve # 20 to obtain uniform 
size granules. Then the final mixture was compressed with 
pressure 2 tons, to achieve tablet hardness around 4 kg/cm
2 
with  acceptable  friability.  Composition  of  the  liquisolid 
formulations is shown in Table 1. 
 
Solubility studies of Metoprolol succinate 
To  select  the  best  non  volatile  solvent  for  suspending  of 
Metoprolol succinate in liquid medication, solubility studies 
of Metoprolol succinate were carried out in 4 different non-
volatile  solvents  i.e.  Water,  PEG  400,  Tween  80  and 
Propylene  glycol  (PG).  Excess  amount  of  metoprolol 
succinate was placed in the different study media (n = 3) and 
was shaken by orbital shaker (REMI RIS-24BL) for 48 h at 
25  ˚C  under  constant  vibration.  After  this  period  the 
saturated  drug  solutions  were  filtered,  diluted  with 
respective solvents (at least 1000 times) and then analyzed 
by  a  UV  -  spectrophotometer  (Jasco  v430,  Japan)  at  a 
wavelength of 274 nm.  
 
Precompression study 
a) Infrared spectra analysis (IR) 
Infrared spectrum of Metoprolol succinate was determined 
on  Fourier  Transform  Infrared  Spectrophotometer  (FTIR- 
4100s)  using  the  KBr  dispersion  method.  The  base  line 
correction was done using dried potassium bromide.  
 
b) Differential Scanning Calorimetry (DSC)  
Thermograms  of  the  samples  (Metoprolol  succinate, 
excipients, and LS systems) were recorded on a DSC (SDT 
Q600  V20.9  Build  20).  Thermal  behavior  of  the  samples 
was  investigated  under  a  scanning  rate  of  10°C/min, 
covering a temperature range of 30–300°C.   
 
c)  Powder-X Ray Diffraction (P-XRD) 
 
X-ray  diffractograms  of  Metoprolol  succinate,  excipients, 
physical  mixture  and  Liquisolid  formulations  were 
performed by using Philips Analytical XRD (PW 3710). The 
cross section of samples was exposed to X-ray radiation (Cr) 
with  wavelength  of  2.28970  °A.  The  scanning  range  was 
from 10-70 
02θ. 
 
d)  The  flow  properties  of  the  Metoprolol  succinate 
Liquisolid system 
The  flow  properties  of  the  Liquisolid  systems  were 
estimated  by  determining  the  angle  of  repose,  Carr’s 
Compressibility  index  (CCI),  and  Hausner’s  ratio  (HR). 
Angle of repose was measured according to the fixed funnel 
and free standing cone method. A funnel with the end of the 
stem cut perpendicular to the axis of symmetry is secured 
with its tip 2 cm height, H, above a graph paper placed on a 
flat horizontal surface. The powders were carefully poured 
through  the  funnel  until  the  apex  of  the  conical  pile  so 
formed just reaches the tip of the funnel. The radius of the 
heap was calculated and tangent of the angle of repose was 
given by: 
θ = tan
-1(H/R)  (1) 
Where, θ is the repose angle, H is the height of the pile and 
R is radius of the pile. 
The Bulk density and Tap densities were determined for the 
calculation  of  Hausner’s  ratio  (HR)  and  Carr’s 
Compressibility Index. (CCI)  
( ) TD - BD
CCI =  100
TD
´    (2) 
T D
H R =
B D
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è ø
     (3) 
Where,  TD  and  BD  are  tapped  density  and  bulk  density 
respectively.  
 
In vitro evaluation  
a) Weight variation test 
The  weight  variation  test  was  performed  as  per  USP  and 
results for all the batches of Metoprolol succinate Liquisolid 
compacts are shown in Table 4. 
 
b) Hardness test 
Hardness  test  was  performed  by  using  the  Monsanto 
Hardness Tester. Results for all the batches of Metoprolol 
succinate Liquisolid compacts are shown in Table 4. 
 
c) Diameter and thickness 
Diameter and thickness were performed by using a digital 
vernier caliper.  
 
d) Friability test 
Friability of prepared compacts was performed using Roche 
Friabilator.  For  friability  test  first  calculating  the  initial 
weight and weight after time t’ resulting in percent weight 
loss  of  each  formulation,  thus  giving  its  friability.  The 
results are expressed in terms of the percentage of weight 
lost during the process.  
 
( ) W0 - Wt
% Weight loss =  100
W0
´    (4) 
Where, W0 = Initial weight, Wt = Final weight 
 
e) Pressure- Relative Density (Heckel plot)  
The granules of Metoprolol succinate liquisolid system (593 
± 5 mg) were compressed by manual tablet punch machine 
using 13 mm flat faced punch and die set at pressures of 1, 
2,  3,  4,  5,  6  and  7  tons  for  1  minute  of  dwell  time  in 
triplicate.  A  1%  w/v  dispersion  of  magnesium  stearate  in 
acetone  was  used  to  carry  out  the  lubrication  of  die  and 
punch.  After  24  hours  of  relaxation  period,  the  weight, 
diameter, and thickness of compacts was measured. The data 
obtained was subject to Heckel equation, 
f
1
ln KyP A
1-P
æ ö
= + ç ÷
è ø  
   
(5) 
 
 
Where  Pf  is  the  packing  fraction  (relative  density)  of 
granules, P as applied pressure, Ky and A (y intercept) were 
the  constants.  Ky  is  equal  to  1/3σ0.Where;  σ0  is  yield 
strength and 3σ0 as mean yield pressure (MyP).  
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f) Pressure - Tensile Strength Relationship 
The same compacts measured in Heckel pilot studies were 
used for Tensile strength (TS) determination in triplicate for 
all batches LS1 to LS9. 
After determination of the diameter (D) and thickness (t), the 
force  (F)  required  to  break  the  compacts  (hardness) 
(Monsanto-type hardness tester) was used to determine the 
TS (σt) using the following equation. 
 
t   
2F
=
Dt p
s  
  (6) 
 
Where, ‘D’ is diameter, ‘t’ is the thickness of compacts; and 
‘F’ is the force required to break the compacts. 
 
g) In vitro dissolution study 
The in  vitro dissolution tests were  performed on the USP 
dissolution  apparatus  II  (paddle  type),  using  900ml 
dissolution medium (pH 1.2 or pH 6.8) with a rotation speed 
of 50 rpm. The dissolution tests for all tablets were run for 2 
h in a simulated gastric fluid (HCl solution, pH 1.2 without 
pepsin)  at  37±0.2  ◦C,  and  subsequently  in  a  simulated 
intestinal fluid (phosphate buffer, pH 6.8 without pancreatin) 
at  37
0C  for  6  h.  Samples  were  collected  at  suitable  time 
intervals (e.g. 15, 30, 60, 90 120, 180, 240, 300, 360, 420 
and 480min). Five milliliters of sample were removed from 
each  dissolution  vessel  and  filtered  through  a  whattman’s 
filter paper (no.42). The same amount of fresh dissolution 
fluid  was  added  to  replace  the  amount  withdrawn.  The 
samples  were  then  analyzed  at  274  nm  by  UV 
spectrophotometer  (Jasco  V  430,  Japan).  All  the  release 
studies  were  conducted  in  triplicate  and  the  mean  values 
were plotted versus time with standard deviation less than 
three indicating reproducibility of results. 
 
In-vivo evaluation of liquisolid compact 
The  protocol  in  prescribed  proforma  B  for  animal  studies 
entitled  “Estimation  of  pharma-  cokinetic  parameters  of 
Metoprolol  succinate  compacts”  was  submitted  on  10
th 
September 2009 to IAEC of Bharati Vidyapeeth College of 
pharmacy,  Kolhapur.  The  protocol  was  approved  by  the 
IAEC  in  the  presence  of  the  CPCSEA  nominee  with 
Approval no. BVCPK/ CPCSEA/ IAEC/33/2009 dated 26
th 
September 2009 at Bharati Vidyapeeth College of pharmacy, 
Kolhapur. 
 
Estimation of Pharmacokinetic parameters 
A  20  µl  of  sample  solution  was  injected  into  the 
chromatography  system  using  the  fixed  volume  loop 
injector. The pharmacokinetic parameters for MS following 
oral  administration  were  determined  from  plasma 
concentration-time  data.  The  maximum  plasma 
concentration  (Cmax)  and  corresponding  time  (tmax)  were 
obtained directly from plasma concentration-time data. The 
Area  under  the  concentration-time  curve  (AUC)  was 
estimated  according  to  trapezoidal  rule.  Elimination  rate 
constant (Kel) was determined by Reppas et al. method 
 
Statistical analysis 
Maximal  plasma  concentration  (Cmax,  ng/ml)  and  time  to 
reach the peak concentration (Tmax, h) were obtained directly 
by  the  plasma  concentration-time  profile.  The  AUC0→t, 
AUC0→∞  (ng  h/ml)  and  t1/2  (h)  were  determined  by  non-
compartmental analysis. The slope of the terminal log-linear 
portion of the concentration-time profile was determined by 
least-squares  regression  analysis  and  was  used  as  an 
elimination rate constant (Kel, h
-1). The elimination half-life 
was  obtained  from  the  formula,  t1/2  =  0.693/  Kel.  The 
AUC0→t from time zero to the last quantifiable point (Ct) was 
calculated using trapezoidal rule and the extrapolated AUC 
from Ct to infinity (AUCt→∞) was determined as Ct/Kel. The 
AUC0→∞  was  computed  through  the  formula,  AUC0→∞  = 
AUC0→t + AUCt→∞ The pharmacokinetic characteristics of 
Metoprolol  succinate  following  oral  administration  of 
directly  compressed  tablets  and  the  prepared  Liquisolid 
compacts were evaluated statistically using one-way analysis 
of  variance  (ANOVA).  Differences  between  two  related 
parameters  were  considered  statistically  significant  for 
P>0.05. All the pharmacokinetic parameters and statistical 
analysis were performed on logarithmically transformed data 
of  Cmax,  AUC0→t,  and  AUCt→∞  using  statistical  software 
package  SYSTAT  (Ver.  12.00.08)  and  Graph  pad  (Ver. 
3.00) graph pad software, San Diego, CA, USA. 
 
Determination  of  Flowable  Liquid  retention  potential 
(Φ- value)  
The corresponding Φ-value calculated from equation 7, 
Φ–value = weight of liquid / weight of solid   (7) 
The  Φ  -values  were  plotted  graphically  against  the 
corresponding angles of slide θ. The Φ-value corresponding 
to an angle of slide of 33
0, represented the flowable liquid 
retention  potential  (Φ–value)  of  powder  excipients.  From 
reported Φ -value the liquid load factor (Lf) and quantities of 
the carrier and coating  materials were  calculated  by using 
the following formulae, 
Lf = Φ + φ (1/ R) 
Φ - Flowable retention potential of carrier material 
φ - Flowable retention potential of coating material 
Lf = W/ Q; Qo = W/ Lo; qo = Qo/R 
 
 
Table 1: Formulation of MS Liquisolid compacts with different drug Concentration 
 
Liquisolid 
System 
Drug concentration in liquid 
medication ( %) 
Liquid medication 
(gm) 
Carrier material 
(gm) 
Coating material 
(gm) 
Tablet wt 
(gm) 
LS-1  10  0.250  1.06  0.053  1.363 
LS-2  12.5  0.200  0.850  0.042  1.092 
LS-3  15  0.167  0.710  0.035  0.912 
LS-4  20  0.125  0.532  0.026  0.683 
LS-5  25  0.100  0.425  0.021  0.546 
LS-6  30  0.083  0.353  0.018  0.454 
LS-7  35  0.071  0.302  0.015  0.388 
LS-8  40  0.062  0.264  0.013  0.339 
LS-9  50  0.050  0.213  0.010  0.273 
All formulations containing, liquid load factor - 0.235, Liquid medication - Tween 80, carrier: coating material ratio - 20 and each formulation contains 
Metoprolol succinate 25 mg. (These excipients calculated according to equation no. 19 to 23) 
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Table 2. Solubility of Metaprolol succinate in different solvent 
 
Solvent  Solubility (mg/ml) 
Tween 80  12.8±0.745 
Propylene glycol  103.7±0.325 
Polyethylene glycol- 400  64.9±0.840 
Water  161.7±0.423 
 
Table 3: Flow properties of MS Liquisolid system 
 
Liquisolid system  Angle of repose (θ)  Carr’s compressibility index  Hausner’s ratio 
LS-1  34.76±1.30  16.67±1.48  1.18±1.50 
LS-2  35.35±1.45  17.34±1.30  1.17±1.21 
LS-3  34.37±1.12  19.87±1.61  1.23±1.32 
LS-4  36.08±1.67  16.66±1.31  1.19±1.65 
LS-5  32.56±1.96  9.09±1.74  1.10±1.72 
LS-6  35.79±1.26  18.21± 1.27  1.24±1.24 
LS-7  34.12±2.54  17.51±1.63  1.27±1.74 
LS-8  38.01±2.33  14.28±1.30  1.17±1.44 
LS-9  35.53±1.15  19.62±1.12  1.25±1.61 
All readings are average ± SD (n=3) 
 
Table 4: Evaluation data for MS Wet Granulation Liquisolid compacts 
 
Formulation 
 
Diameter 
 (mm) 
Thickness  
(mm) 
Hardness 
(Kg/cm
2
) 
Wt. Variation 
(gm) 
Friability 
(%) 
LS-1  13.16± 0.123  5.04± 0.013  5  1.363±0.142  0.095 ± 0.007 
LS-2  13.17± 0.152  4.92± 0.061  5  1.092±0.074  0.126 ± 0.003 
LS-3  13.21± 0.333  4.84± 0.073  5  0.912±0.152  0.274 ± 0.002 
LS-4  13.23± 0.264  4.21± 0.044  5  0.683±0.476  0.089± 0.006 
LS-5  13.16± 0.177  3.65± 0.070  5  0.546±0.159  0.072± 0.008 
LS-6  13.22± 0.149  3.31± 0.087  4  0.454±0.176  0.099± 0.002 
LS-7  13.17± 0.153  2.95± 0.054  4  0.388±0.081  0.094± 0.003 
LS-8  13.22± 0.123  2.42± 0.061  4  0.339±0.270  0.199 ± 0.006 
LS-9  13.18± 0.173  2.19± 0.042  4  0.273±0.197  0.168± 0.002 
All readings are average ± SD (n=3) 
 
Table 5: Pharmacokinetic data for MS Liquisolid compacts and conventional matrix tablet in plasma 
 
Sr. No.  Pharmacokinetic parameters  Liquisolid compacts
a  Conventional matrix tablet
a  P-value 
b 
1  AUC0-24 ng h ml
-1  16710.4±685  14736.7±1241  0.0252(S) 
2  AUC0-∞ ng h ml
-1  20728.5±1537  17631.3±1129  0.0363(S) 
3  Cmax, ng ml
-1  1115.9±78  1022.2±29  0.0379(S) 
4  Tmax. h  12.52±0.6  12.11±0.5  0.2458(NS) 
5  Kel, h
-1  0.204±0.14  0.224±0.34  0.4352(NS) 
6  t1/2. H  3.40±0.12  3.12±0.65  0.2486(NS) 
a Mean ± SD (n=3), b P- value of the variance., S- Significant; NS- Not significant 
 
 
 
Figure 1:  Overlain IR spectrum of Metoprolol succinate and LS-5 formulation 
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Figure 2: Differential scanning calorimeter plot of liquisolid formulation (LS-5) and pure Metoprolol succinate. 
 
 
 
Figure 3:  X-ray diffractograms of (A) Pure MS, (B) Physical Mixture (C) Liquisolid powder system (D) Avicel PH 102 
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Figure 4. Effect on drug release retardation property by wet granulation method 
 
 
 
Figure 5. Mean metoprolol succinate plasma profiles following single-dose, A crossover bioavailability study comparing MS conventional Matrix 
and liquisolid tablets. 
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RESULT AND DISCUSSION 
Metoprolol was selected as the model drug for these studies 
since it is a water soluble drug and a suitable candidate for 
testing the potential of sustained release liquisolid compacts. 
All  the  standard  curves  of  metoprolol  succinate  solutions 
obeyed Beer’s law which was linear over the concentration 
range tested since 5-30 µg/ml. Their results are presented in 
Table 2. 
The  flow  properties  of  the  Liquisolid  powder  system  are 
affected by physical, mechanical as well as environmental 
factors. Therefore different flow parameters were employed 
such as, the angle of repose (θ), Carr’s compressibility index 
and Hausner’s ratio and their results are presented in Table 
3. 
 
IR spectrum of Metoprolol succinate (IR) 
In which characteristic peaks of aromatic N-H stretching at 
3399.89 cm
-1and peak at 3734.48 cm
-1 indicating presence of 
O-H  group, and  peak at 1508.06 cm
-1 indicating aromatic 
C=C  group.  (Figure  1)  shows  overlain  IR  spectrum  of 
formulation and drug shows no interaction between drug and 
excipients.   
 
Differential scanning calorimetry (DSC) 
The  possible  interactions  between  a  drug  entity  and 
excipients in Liquisolid compacts were determined by DSC. 
(Figure  2)  reveals  the  thermal  behaviors  of  the  pure 
components together with the thermal behavior of the final 
Liquisolid system prepared. Metoprolol succinate peaks are 
clear, demonstrating a sharp characteristic endothermic peak 
at 146.03°C corresponding to its melting temperature (Tm); 
such  sharp  endothermic  peak  signifies  that  Metoprolol 
succinate used was in a pure crystalline state. The liquisolid 
(LS-5)  formulation  showed  the  same  peaks  in  this  area, 
which indicates that there is no interaction between drug and 
excipients  during  the  formulation  process.  From  above 
finding it can be concluded that the delayed dissolution rate 
of Metoprolol succinate liquisolid compacts is not due to the 
formation of the complex between the drug and excipients or 
changes in crystallinity of the drug.      
 
Powder-X-Ray Diffraction (P-XRD) 
Polymorphic changes of drugs are important factors which 
might affect the dissolution rate and in turn bioavailability. It 
is  necessary  to  study  polymorphic  changes  of  MS  in 
Liquisolid compacts. The pharmaceutical implication of the 
presence of meta stable crystalline forms in the excipients is 
well recognized. The crystal structure could also affect tablet 
porosity  and  density,  the  mechanism  of  aggregation  and 
disintegration and the plastic and elastic properties of solid 
dosage forms (Bartolomei et al, 1999). (Figure 3) shows the 
P-XRD of pure MS, pure excipients, physical mixture and 
Liquisolid system. Metoprolol succinate shows (Figure 3 A) 
sharp peaks at 10.47, 20.97, 21.205, 30.035 and 36.355
02θ. 
Liquisolid  powder  system  shows  (Figure  3  C)  sharp 
diffraction peak at 30.010 at 
02θ and Avicel PH 102 shows 
(Figure 3 D) sharp diffraction peak at 34.29, which indicate 
Avicel  PH  102,  also  maintained  its  crystalline  state.  As 
above Figure 3, liquisolid and physical mixture (Figure 3 
B) formulations have relatively the same diffraction pattern 
with minor changes which some  of them  could be due to 
peak  noises.  A  reduction  in  peak  height  and  sharpness  in 
peaks  might be due to lower concentration of the drug in 
these  formulations  in  comparison  with  pure  drug  powder. 
Comparing the some changes in peak ratio of pure drug and 
liquisolid formulations might be changes in the polymorphic 
ratio of the drug in the formulations. It can be concluded that 
no  significant  interaction  between  drug  and  polymers 
occurred during the formulation process.  
 
Evaluation of MS Liquisolid compacts: 
The  results  of  Diameter,  thickness,  Hardness,  weight 
variation  and  friability  test  for  all  the  batches  of  wet 
granulation MS Liquisolid compacts are shown in Table 4. 
The  evaluations  were  performed  on  LS-1  to  LS-9 
formulations, the lowest percent weight loss was found to be 
in LS-5 formulation. All the selected metoprolol succinate 
liquisolid  tablets  had  acceptable  friability  as  none  of  the 
tested formulae had a percentage loss in tablet weights that 
exceed 0.5%. Also no tablet was cracked, split or broken in 
all these formulations.  
 
In vitro dissolution studies 
(Figure 4.) Shows the drug release retardation properties of 
LS-5  direct  compression  tablet  and  LS-5  wet  granulation 
compacts  of  Metoprolol  succinate.  In  this  study  wet 
granulation  technique  shows  more  retardation  properties 
compare to direct compression technique. It was found that 
wet granulation had a remarkable impact on the release rate 
of  metoprolol  succinate  from  liquisolid  compacts.  It  was 
reported that granulation of diclofenac sodium using HPMC 
can slow down the release of the drug in comparison with 
dry  technique.  This  could  be  due  to  the  coating  of  drug 
particles  by  HPMC  during  the  granulation  process  which 
sequentially retard the penetration of water into the granules 
or  reduce  the  direct  contact  of  the  drug  with  dissolution 
medium.  Finally  we  could  find  that  granulation  process 
induced  the  slow  release  effect  or  that  was  the  retarding 
effect  of  HPMC,  physical  dry  mixture  of  liquisolid  and 
HPMC was prepared and the results of dissolution tests were 
compared. The results showed that there was no significant 
difference between the drug release profile of physical dry 
mixture of liquisolid formulation and LS formulation with 
HPMC.  On  the  other  hand  significant  difference  was 
observed  between  granulation  liquisolid  formulation  and 
granulation  LS  formulation  with  HPMC.  These  results 
confirmed  the  effect  of  a  granulation  method  on  the 
sustained release behavior of liquisolid tablets.  
 
Estimation of pharmacokinetic parameters of MS 
liquisolid compact 
(Figure 5.) Shows Plasma concentration verses time profile 
of MS Liquisolid compacts and conventional matrix tablet. 
Liquisolid compacts show higher concentrations of MS in 
plasma  as  compared  to  conventional  matrix  tablets. 
Liquisolid  compacts  demonstrate  better  bioavailability 
which  can  be  confirmed  from  pharmacokinetic  data 
expressed in Table 5. 
 
Statistical analysis 
The mean plasma concentration–time profiles of Metoprolol 
succinate  following  the  oral  administration  of  the 
conventional  matrix  Metoprolol  succinate  tablets  and  the 
prepared liquisolid tablets (LS-5) are shown in Figure 5 and 
the calculated pharmacokinetic parameters are presented in 
Table  5.  Crossover  and  multiple  dose  study  should  be 
carried out to ensure the formulation of drug to consider for 
clinical trial. 
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CONCLUSION 
The present work showed that liquisolid technique can be 
optimized for the production of sustained release matrices of 
water-soluble  drugs.  Tween  80  was  used  as  the  liquid 
vehicle the release of drug from these formulations followed 
zero-order  release  kinetics.  This  investigation  provided 
evidence that polysorbate 80 (Tween 80) has an important 
role  in  sustaining  the  release  of  drug  from  liquisolid 
matrices. Heat treatment had no effect on the release profile 
of  drug  from  liquisolid  tablets.  Hardness  and  dissolution 
profile  of  the  drug  were  not  affected  by  aging.  No 
crystallinity  change  was  observed  during  the  process  of 
liquisolid formulation. The proposed new technique can be 
used in the preparation of sustained release formulations of 
water-soluble drugs such as metoprolol succenate.  
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